Federal Register Notice: FDA will hold a public conference 3/18-19/15 entitled “Serious Drug-Induced Liver Injury (DILI): The Importance of Getting It Right: How to Measure and Interpret DILI Information and Make Correct Diagnoses.” It will be co-sponsored with the Critical Path Institute and Pharmaceutical Research and Manufacturers of America. Its purpose is to discuss how best to detect and assess the severity, extent, and likelihood of drug causation of liver injury and dysfunction in people using drugs for any medical purpose. It will be held 3/18/15, from 8 a.m. to 6 p.m. and 3/19, from 8 a.m. to 4 p.m. at the College Park Marriott Hotel & Conference Center, 3501 University Blvd., Hyattsville, MD. Contact Lana L. Pauls (301) 796-0518, email: lana.pauls@fda.hhs.gov. To view this notice, click here.